Overview

Phase II Study of Perindopril and Regorafenib in mCRC

Status:
Completed
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects the combination of regorafenib and perindopril has on hand-foot skin reaction (HFSR), on high blood pressure (hypertension) and on any other types of side-effects and compare it to the published incidence of the side-effects with regorafenib alone. This research is being done in an attempt to reduce the side-effects associated with regorafenib.
Phase:
Phase 2
Details
Lead Sponsor:
British Columbia Cancer Agency
Collaborator:
Bayer
Treatments:
Perindopril